Table 2.
Change rates of LDL-C levels at 12 weeks from baseline in two treatment groups.
| LDL-C changes | Hybutimibe plus atorvastatin (n = 128) | Atorvastatin (n = 125) | P-value | |
|---|---|---|---|---|
| mITT | Pre-treatment, mmol/L | 2.61 ± 0.30 | 2.58 ± 0.31 | 0.3938 |
| 12 weeks, mmol/L | 2.18 ± 0.45 | 2.40 ± 0.46 | 0.0001 | |
| Changes P-value |
<0.0001 | <0.0001 | ||
| Rate of changes (95% CI) | −16.39 (−19.04, −13.74) |
−6.75 (−9.48, −4.02) |
<0.0001 | |
| Adjusted rate of changes (95% CI)* | −16.33 (−18.99, −13.67) |
−6.82 (−9.51, −4.13) |
<0.0001 | |
| Adjusted rate of changes, (95% CI)# | −16.24 (−18.94, −13.54) |
−6.80 (−9.51, −4.08) |
<0.0001 | |
| PPS | Pre-treatment, mmol/L | 2.64 ± 0.30 | 2.55 ± 0.30 | 0.0557 |
| 12 weeks, mmol/L | 2.18 ± 0.44 | 2.32 ± 0.41 | 0.0183 | |
| Changes P-value |
<0.0001 | <0.0001 | ||
| Rate of changes (95% CI) | −17.21 (−20.39, −14.02) |
−8.86 (−11.79, −5.93) |
0.0002 | |
| Adjusted rate of changes (95% CI)* | −16.87 (−19.87, −13.86) |
−9.21 (−12.24, −6.17) |
0.0005 | |
| Adjusted rate of changes (95% CI)# | −16.83 (−19.91, −13.75) |
−9.12 (−12.20, −6.04) |
0.0007 | |
*
Adjusted for LDL-C levels at baseline.
#Adjusted for LDL-C at baseline, age, and BMI.
LDL-C, low-density lipoprotein cholesterol; mITT, modified intention-to-treat; CI, confidential interval; PPS, per-protocol set; BMI, body mass index.